Purpose. The tumour suppressor protein RB plays a decisive role in negative control of the cell cycle, inhibiting tumour development. The present analysis investigated the prevalence of the nucleotide polymorphism A153104G, which is located at intron 18 of the RB1 gene, and investigated the impact of the polymorphic variability in the exon 19 and its flanking intronic sequences on the severity of cervical disease in HPV16-positive Greek women.
INTRODUCTION
Human papillomaviruses (HPVs) comprise a heterogeneous group of small, non-enveloped, capsid-enclosed dsDNA viruses that infect the mucosal and cutaneous epithelia [1, 2] . The HPV genotypes are classified into five distinctive genera -alpha, beta, gamma, mu and nu [3] [4] [5] [6] . The alphapapillomaviruses can be further sub-divided into high-risk and low-risk genotypes based on their relationship with disease malignancy [1, 4, 5] . It is unambiguously accepted that persistent infection with high-risk HPV genotypes is indispensable for the growth of high-grade squamous intraepithelial lesions (HSIL) and cancer of the uterine cervix, which is the fourth most common cause of cancer mortality among women worldwide [2, 7, 8] . Epidemiological studies have implied that HPV16 and HPV18 are the two most tumorigenic genotypes, accounting for about 50 and 20 % of cervical cancer cases, respectively [9, 10] .
The sustained expression of the high-risk E6 and E7 oncoproteins plays a pivotal role in the induction and maintenance of cervical disease, since they constrain the function of the tumour suppressor protein p53 and the retinoblastoma protein pRB, respectively [11] [12] [13] [14] . The tumour suppressor protein RB is a chromatin-related protein that controls cellular proliferation through the regulation of the E2F transcription factor [15] [16] [17] [18] . In particular, the cyclindependent kinases CDK4, CDK6 and CDK2 are activated in response to mitogenic stimuli and phosphorylate the pRB [19] [20] [21] . The hyperphosphorylated form of pRB enables the detachment of pRB from E2F transcription factor. The free form of E2F promotes cell cycle progression, coordinating the recruitment of transcriptional co-activators to promoters of genes that are implicated in the mitotic proliferation [22, 23] . Upon cell cycle progression, the reduction of CDK function and the activity of protein phosphatase 1 (PP1) facilitate the formation of the pRb/E2F complex, which acts as a transcription suppressor of these genes [22, 23] . With regard to HPV infection, the E7 oncoprotein disrupts the pRB/E2F suppressor complex, releasing the E2F transcription factor, which in turn promotes the mitotic phase of the cell cycle and finally leads to tumour growth [14] [15] [16] .
The tumour suppressor protein RB is encoded by the the retinoblastoma susceptibility gene (RB1), which is located on chromosome 13q14.12-13q14.2 and comprises 27 exons that generate a protein of 928 amino acids [24] . The structural analysis of pRB revealed two (small and large) pocket regions. The small pocket region comprises the A and B domains, which are separated by a flexible spacer region [16, 23] . The small pocket region is implicated in the interaction of pRB with viral oncoproteins that harbour the peptide motif LXCXE. The small pocket and the C-terminal portion of pRB compose the large pocket region that is involved in the interaction of pRB with the E2F transcription factor [16] .
A previous analysis in the Indian population revealed that the nucleotide polymorphism A153104G that is located at intron 18 of the RB1 gene (rs4151580) affects the vulnerability of patients to cervical cancer growth [25] . However, no further analyses have been performed to investigate the prevalence of the respective polymorphism in patients with cervical dysplasia at different geographical locations and among different ethnic groups, while no further sequence variations in RB1 gene have been associated with the development of cervical disease.
In the present report, a study on HPV16-positive precancerous cases and controls was performed in order to examine the prevalence of the A/G SNP (Single Nucleotide Polymorphism) at position 153104 of the RB1 gene in the Greek population. Our goal was to further investigate the association of the respective RB1 variant with the risk of more severe dysplasia in HPV16-positive Greek women. Furthermore, the nucleotide sequence of the exon 19 of the RB1 gene and its flanking intronic sequences was investigated in order to identify the nucleotide variations that are prevalent in the Greek population and assess whether this variability influences the susceptibility of Greek women to cervical disease. Towards this end, we evaluated the selective pressure acting on the exon 19 among the different stages of cervical disease and the control group.
METHODS

Cervical samples
A prospective study that recruited a total of 48 women who were positive for HPV16 infection was carried out. The women attended the colposcopy clinic of the 3rd Department of Gynecology and Obstetrics in the tertiary care 'ATTIKON' University General Hospital between June 2013 and June 2015. The study population did not represent a normally screened population, since most patients attended the outpatient clinics after a referral for abnormal cytology and/or colposcopy. Twenty-two samples were diagnosed as low-grade squamous intraepithelial lesions (LSILs) and 26 samples were diagnosed as high-grade squamous intraepithelial lesions (HSILs), while the control group comprised 60 cervical samples with normal cytology and without HPV16 infection. All patients signed an informed consent form, while the study was approved by the Bioethics Committee of the hospital (approval number 5/14-06-2013).
DNA isolation and HPV16 DNA detection Genomic DNA was extracted from ThinPrep samples from patients and controls, respectively, using the chaotropic agent guanidine thiocyanate (GuSCN) [26] . The identification of HPV16 DNA was performed by a previously described methodology of multiplex PCR using L1 typespecific primer sets [27] .
Detection of the sequence variation A153104G of the RB1 gene via PCR-RFLP In the present analysis, it was considered whether the nucleotide variation A153104G of the RB1 gene that is prevalent in the Indian population and is associated with increased risk of cervical disease development is also distributed in HPV16-positive Greek patients. The sequence variation A153104G of the RB1 gene was detected using the PCR-RFLP methodology [28] . Briefly, a 485 bp fragment was amplified by PCR using the forward primer 5¢-AGGCAG TAATCCCCAGGAAAAGCCA-3¢ and the backward primer 5¢-CACAGAGATATTAAGTGACTTGCCC-3¢. The amplified fragment contained a partial fragment of intron 18 (residues 152986 to 153207), the complete ORF of exon 19 (residues 153208 to 153353) and a partial fragment of intron 19 (residues 153354 to 153469). Finally, the amplicons were digested with the MluCI restriction enzyme (New England Biolabs, Ipswich, MA, USA) for the identification of the nucleotide variation (A/G) at position 153104 of the RB1 gene. C. The first cycle was proceeded by a 2 min denaturation step at 95 C and the final cycle was followed by a 5 min elongation step at 72 C. Subsequently, the amplified fragments were digested with 20 units of MluCI restriction enzyme (New England Biolabs, Ipswich, MA, USA) at 37
C for 1 h. The restriction enzyme was certified by New England Biolabs as a Time-Saver qualified restriction enzyme, meaning that DNA can be digested either in 5-15 min, or safely overnight. The outcomes of digestion were monitored in a 2 % agarose gel containing 1 µg of ethidium bromide ml À1 in Tris/borate/EDTA buffer using a 100 bp DNA ladder (Invitrogen, Life Technologies, Paisley, UK) as a molecular weight marker.
Cloning and sequence analysis of the exon 19 of the Rb1 gene and its flanking intronic sequences The sequence of exon 19 and its flanking regions were further examined through the cloning and sequencing of all the examined cervical samples. In particular, each individual amplicon was subjected to cloning using the pGEM T-easy vector system (Promega, Madison, WI, USA). The recombinant plasmid DNA was purified through the Nucleospin plasmid kit (Macherey Nagel, Duren, Germany) and the plasmids were sequenced at Macrogen Europe, Amsterdam, The Netherlands. The cloned sequences were characterized by a database search at the National Centre for Biotechnology Information (NCBI) website with the MEGABLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The analysis of the sequence variations of exon 19 and its flanking regions and the detection of the amino acid substitutions of exon 19 were implemented via multiple sequence alignment among the reference sequence of the RB1 (GenBank accession number: L11910) and the cloned sequences that were collected from the present analysis, using the MUSCLE alignment algorithm in MEGA v.5 software [29, 30] .
Selection analysis
The maximum-likelihood (ML) and empirical Bayesian (EB) methods were used to estimate the selective pressure acting upon the exon 19 of the RB1 gene. The ML analysis was implemented using the fixed effects likelihood model (FEL) that is incorporated in the online software platform Datamonkey in order to calculate the d N /d S ratio (d N , nonsynonymous changes per non-synonymous site; d S , synonymous changes per synonymous site) at every site [31, 32] . For the FEL method, a codon was considered to be positively selected at a cutoff P-value of 0.05. In addition, the median mutation rate in the first, second and third positions of the exon 19 of the RB1 gene were calculated using Bayesian Markov chain Monte Carlo (MCMC) analysis, which is included in the BEAST v.1.6.2 software package [33] . The parameter settings were specified using BEAUti v.1.6.2 [33] and the analyses were conducted with BEAST. Briefly, the Bayesian MCMC analysis comprised four chains with random starting trees and the convergence was estimated with effective sample sizes (ESS) greater than 200 after a burning of 1Â10 6 steps. The runs were evaluated using TRACER v.1.5 [33] . For the ML and EB analyses we utilized the most suitable substitution model according to the Akaike information criterion using FindModel online software (www.hiv. lanl.gov/content/sequence/findmodel/findmodel.html). In particular, the Hasegawa-Kishino-Yano (HKY) substitution model was selected to analyse the cohort of control cervical cases, while the Tamura-Nei (TrN) substitution model was preferred to assess the groups of LSIL and HSIL cervical samples.
RESULTS
In the current study we determined the prevalence of the nucleotide polymorphism A153104G (intron 18 of the RB1 gene) in HPV16-positive Greek patients (LSILs and HSILs) and control cases. Considering the results from the present analysis it was observed that the A153104G nucleotide change was only detected in one control case (LBC20), while it was not identified in any of the LSIL or HSIL cervical samples. Moreover, the extensive sequence analysis of the amplicons that were collected from each individual cervical specimen confirmed the initial outcomes of the PCR-RFLP assay.
The sequence variations that were detected in exon 19 and its flanking regions as well as the amino acid substitutions that were recorded in the ORF of exon 9 in the control, HSIL and LSIL cases are listed in Table 1 . The sequence analysis of the corresponding fragment of RB1 gene revealed that this particular region of the human genome is conserved among the examined control cases. However, six different nucleotide variations were detected in a total of five different control cervical samples (Table 1 ). In particular, in the partial fragment of intron 18 of the RB1 gene (residues 152986 to 153207) the control case LBC10 revealed the nucleotide change T153077C, while the control sample LBC20 showed the nucleotide variations A153104G and T153130C. In the exon 19 of the RB1 gene (residues 153208 to 153353) the cervical samples LBC72 and LBC68 harboured the synonymous mutations A153278G and T153326C, respectively, while in the partial fragment of intron 19 of the RB1 gene (residues 153354 to 153469) the control sample LBC66 revealed the nucleotide change T153373G (Table 1) .
For the LSIL cervical samples, ten different variations were identified in a total of eight different LSIL cervical specimens (Table 1) . Specifically, in the partial fragment of intron 18 of the RB1 gene the LSIL cervical specimen LBC28 carried the nucleotide changes T153033C, T153126C and A153173G, while the cervical samples AG3670, AG3500 and ATT14 had the mutations T153011C, A153133T and T153188C, respectively. Moreover, in the exon 19 of the RB1 gene the cervical case LBC29 demonstrated the synonymous nucleotide variation T153215C, while the cervical specimen LBC36 revealed the sequence variation C153268T, which results in the amino acid substitution T625I. The sequence analysis of intron 19 of the RB1 gene showed that the LSIL cervical samples LBC31 and ATT45 harboured the nucleotide changes T153408C and A153413G, respectively ( Table 1 ).
The corresponding fragment of the RB1 gene was found to be polymorphic among the HSIL cervical samples, since 50 different nucleotide mutations were identified in a total of 13 different HSIL cervical cases (Table 1 ). In particular, 20 different nucleotide variations were described in 11 cervical samples after sequence analysis of the partial fragment of intron 18 of the RB1 gene. In the exon 19 of the RB1 gene, a total of 20 different non-synonymous variations were described, while 5 nucleotide changes were characterized as silent nucleotide mutations. Moreover, in the intron 19 of the RB1 gene five different nucleotide mutations were found in a total of three cervical specimens (Table 1) . When the results from the sequence analysis of different HSIL cervical cases were considered together it was observed that four different nucleotide changes are present in more than one cervical sample. In particular, in the partial fragment of intron 18 of the RB1 gene the nucleotide variation G153093A was detected in three HSIL cases (LBC44, AG3629 and D3), the sequence change T153194A was identified in two HSIL samples (LBC56 and AG3591) and the nucleotide variation A153197G was prevalent in three HSIL specimens (LBC56, AG3629 and D3). Moreover, in the region of exon 19 of the RB1 gene the synonymous sequence variation T153245C was detected in two HSIL cases (AG3629 and D3) ( Table 1) . Finally, merging the results from the sequence analysis of the RB1 gene among the control, LSIL and HSIL samples showed that the nucleotide variation T153033C, which is 
located in the intron 18 of the RB1 gene, is common in the LSIL cervical sample LBC28 and the HSIL cervical specimen AG3578. Moreover, nucleotide position 153408 (intron 19 of RB1 gene) was found to be polymorphic between the LSIL sample LBC31 (T153408C) and the HSIL case LBC52 (T153408A) ( Table 1) .
Selective pressure analysis of the exon 19 of the RB1 gene revealed that the group of control cervical cases had d N /d S <1 and the relative substitution rates for all three codon positions were CP1=0.6, CP2=0.6 and CP3=1.8. Moreover, in the group of LSILs, the FEL analysis estimated d N /d S <1, whereas the relative substitution rates for all three codon positions were CP1=0.6, CP2=1.18 and CP3=1.2. The cohort of HSILs had d N /d S >1 , whereas the relative substitution rates for all three codon positions were CP1=1.025, CP2=1.222 and CP3=0.753.
DISCUSSION
The tumour suppressor protein RB is a member of the pocket protein family that comprise RB (p105, RB1 gene), p107 (RBL1 gene) and p130 (RBL2 gene). The pRB plays a fundamental role in negative control of the cell cycle, since it orchestrates the regulation of the G1 checkpoint, inhibiting the transition from G1 to S and constraining cell proliferation and consequently tumour growth [15, 16, 20, 34] . Several investigations have determined that the majority of human cancers encompass either mutations in the RB1 gene or mutations in genes that are implicated in the RB pathway [16, 17, 25, 35, 36] . Given the mutations in the RB1 gene, it has been suggested that point mutations are assigned throughout the gene, while particular mutational hotspots are located within the retinoblastoma pocket domain that harbours the coding regions of exons 12-23 [37] [38] [39] [40] . Recently, it has been observed that point mutations in the RB1 gene or genetic ablation are involved in angiogenesis, epithelial-to-mesenchymal transition, migration, invasion and metastasis [35] [36] [37] [38] [39] [40] [41] . Moreover, viral oncoproteins are also involved in dysfunction of the RB-E2F pathway, leading to a variety of dysplasias, including cervical cancer, mesothelioma and AIDS-associated Burkitt's lymphoma [42, 43] .
Although the polymorphic variability in the RB1 gene has been investigated to a considerable extent in several types of cancer, the prevalence of particular polymorphisms in the RB1 gene, as well as their association with the risk of cervical disease, remains rather vague [25] . Notably, a previous analysis by Thakur et al. [25] suggested that the nucleotide polymorphism A153104G, which is located at exon 18 of the RB1 gene, is to a considerable extent implicated in cervical cancer growth in the Indian population. No further studies concerning the relationship between the nucleotide variation A153104G and the risk of cervical dysplasia were conducted. Therefore, the present analysis investigated the distribution of the A153104G sequence variation in the Greek population in order to elucidate whether this polymorphism influences patients' susceptibility towards the development of HPV16-associated LSILs and HSILs and further analysed the sequence of the exon 19 of the RB1 gene and its flanking intronic sequences in order to examine the impact of the polymorphic variability in the RB1 gene on the severity of cervical disease in the Greek population.
The present analysis revealed that the nucleotide polymorphism A153104G is not prevalent in the Greek population. It was only detected in one control sample (LBC 20), while it was not identified in any of the examined LSIL or HSIL cervical specimens, leading to the assumption that this polymorphic alteration is not involved in the development of HPV16-associated precancerous lesions in Greek patients. [25] . Cervical cancer cases were not incorporated in the present analysis and thus the impact of polymorphism A153104G on cervical cancer risk in the Greek patients remains to be further investigated. However, it is noteworthy that the polymorphism A153104G has only been observed in Asian populations [25, 44, 45] , while it has not been observed in patients from different geographical areas who are positive for different types of cancer. Specifically, the corresponding polymorphism has not been detected in either British patients with breast cancer or in patients from the United Kingdom, the United States and Denmark with ovarian cancer [46, 47] . Taking all these data into consideration, we anticipated that different polymorphisms that are prevalent in diverse geographical locations and ethnic groups have different impacts on tumour growth in populations with different genetic backgrounds. Hence, the determination of specific SNPs in the RB1 gene may provide considerable insights regarding the outcome of an HPV16 infection and the progress of cervical disease in specific geographical populations in particular.
Interestingly, in the present study the sequence analysis of the RB1 gene in Greek patients with cervical dysplasia demonstrated that the sequence variations G153093A, T153194A, A153197G and T153245C were identified in more than one HSIL cervical sample, while the nucleotide changes T153033C and T153408C/A were detected in both LSIL and HSIL cases (Table 1) . These sequence changes could not be associated with the risk of cervical disease and consequently further investigations are required in order to investigate their prevalence in the Greek population and assess their role in cervical disease development. These outcomes reinforce our primary hypothesis that specific nucleotide polymorphisms might be prevalent in different populations and ethnic cohorts and thus their role in the development of cervical disease must be elucidated.
Although no specific nucleotide polymorphism was associated with the risk of cervical disease in the Greek population, the sequence analysis of the exon 19 and its flanking intronic sequences revealed considerable polymorphic variability in the RB1 gene that increased with the severity of the cervical lesions ( Table 1 ). The corresponding region of the RB1 gene was found to be conserved in the control and LSIL samples, while it was polymorphic among the HSIL cervical cases ( (Table 1) . It is significant to highlight that the exon 19 encodes for the flexible spacer region that separates the A and B domains of the small pocket region of pRB [25, 48] . Therefore, it was anticipated that the accumulation of sequence variations in the exon 19 in HSIL cervical cases might affect the function or structure of the flexible spacer region of pRb negatively, which leads to the hypothesis that the activity of pRb or the interaction of pRB with the HPV16 E7 oncoprotein might be modified [24] . As a result, the accumulation of amino acid substitutions in the flexible spacer region of pRB might act synergistically with HPV16 infection, influencing patients' susceptibility towards the development of more severe dysplasia. However, further studies are required to clarify this hypothesis.
In conclusion, this is the first study to describe the distribution of the nucleotide polymorphism A153104G in HPV16-infected Greek women, and the results suggest that this polymorphic alteration cannot be used as a potential biomarker for the growth of precancerous neoplasia in Greek patients. Moreover, the results derived from the sequence and molecular evolutionary analyses indicate that the accumulation of sequence variations in the RB1 gene might increase patients' vulnerability to the progression of cervical disease and therefore further analyses must be performed to assess the clinical significance of the polymorphic variability of the RB1 gene in the development of cervical dysplasia.
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